NCT01971164View on ClinicalTrials.gov

Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease

PHASE1CompletedINTERVENTIONAL

Enrollment

29

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

May 31, 2014

Study Completion Date

July 31, 2014

Conditions

Anemia of Chronic Kidney Disease

Interventions

DRUG

JTZ-951

Subjects will receive JTZ-951 or Placebo

DRUG

Placebo

Trial Locations (5)

Unknown

Lakewood

Miami

Orlando

Minneapolis

Saint Paul

Sponsors

Lead Sponsor

Akros Pharma Inc.

All Listed Sponsors

lead

Akros Pharma Inc.

INDUSTRY

NCT01971164 - Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease | Biotech Hunter | Biotech Hunter